• Citer

A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: The GAMMA trial

par Fuchs, Charles C.S.;Bodoky, G.;Ikeda, Masafumi;Melichar, Bohuslav;Nemecek, R.;Ohkawa, Shinichi;Swieboda-Sadlej, Anna;Tjulandin, Sergei;Van Cutsem, Eric;Loberg, Robert;Haddad, Vincent;Azevedo, Sergio;Gansert, Jennifer J.L.;Bach, Bruce B.A.;Carrato, Alfredo;Okusaka, Takuji;Van Laethem, Jean-Luc ;Lipton, Lara L.R.;Riess, Hanno;Szczylik, Cezary;Moore, Malcolm J;Peeters, Michel
Référence Annals of oncology, 26, 5, page (921-927), mdv027
Publication Publié, 2015-05

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: The GAMMA trial
Auteur:	Fuchs, Charles C.S.; Bodoky, G.; Ikeda, Masafumi; Melichar, Bohuslav; Nemecek, R.; Ohkawa, Shinichi; Swieboda-Sadlej, Anna; Tjulandin, Sergei; Van Cutsem, Eric; Loberg, Robert; Haddad, Vincent; Azevedo, Sergio; Gansert, Jennifer J.L.; Bach, Bruce B.A.; Carrato, Alfredo; Okusaka, Takuji; Van Laethem, Jean-Luc; Lipton, Lara L.R.; Riess, Hanno; Szczylik, Cezary; Moore, Malcolm J; Peeters, Michel
Informations sur la publication:	Annals of oncology, 26, 5, page (921-927), mdv027
Statut de publication:	Publié, 2015-05
Sujet CREF:	Hématologie
	Cancérologie
Mots-clés:	Biomarker
	Ganitumab
	Gemcitabine
	IGF-1 receptor
	Pancreatic cancer
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:0923-7534
	info:doi/10.1093/annonc/mdv027
	info:scp/84929083437